Adjuvant Trastuzumab in HER2-Positive Breast Cancer

BACKGROUND: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Slamon, Dennis, Eiermann, Wolfgang, Robert, Nicholas, Pienkowski, Tadeusz, Martin, Miguel, Press, Michael, Mackey, John, Glaspy, John, Chan, Arlene, Pawlicki, Marek, Pinter, Tamas, Valero, Vicente, Liu, Mei-Ching, Sauter, Guido, von Minckwitz, Gunter, Visco, Frances, Bee, Valerie, Buyse, Marc, Bendahmane, Belguendouz, Tabah-Fisch, Isabelle, Lindsay, Mary-Ann, Riva, Alessandro, Crown, John
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3268553/
https://ncbi.nlm.nih.gov/pubmed/21991949
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa0910383
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items